[{"id":"71c0a42c-6796-493e-910c-e7f74252415b","acronym":"CLN-619-001","url":"https://clinicaltrials.gov/study/NCT05117476","created_at":"2022-05-06T19:54:01.352Z","updated_at":"2025-02-25T17:01:30.662Z","phase":"Phase 1","brief_title":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT05117476 - CLN-619-001","lead_sponsor":"Cullinan Therapeutics Inc.","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CLN-619"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-03"}]